These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9499441)

  • 1. Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy.
    Nomura Y
    Int J Oncol; 1998 Apr; 12(4):817-24. PubMed ID: 9499441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
    Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
    Cancer; 1996 Feb; 77(4):683-90. PubMed ID: 8616760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials.
    Kuss JT; Muss HB; Hoen H; Case LD
    Breast Cancer Res Treat; 1997 Feb; 42(3):265-74. PubMed ID: 9065610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to second line chemo-endocrine treatment may prolong the overall survival of advanced breast cancer patients.
    Nomura Y
    Anticancer Res; 1997; 17(2B):1425-30. PubMed ID: 9137509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocrine therapy of recurrent breast cancer].
    Nomura Y; Tashiro H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):421-7. PubMed ID: 3890756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
    Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
    Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
    Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
    J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
    Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
    J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized trial of endocrine therapy, chemotherapy, and chemo-endocrine therapy in advanced breast cancer].
    Tashiro H; Nomura Y; Hisamatsu K
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2369-73. PubMed ID: 2260873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients.
    Alanko A; Heinonen E; Scheinin T; Tolppanen EM; Vihko R
    Cancer; 1985 Oct; 56(7):1696-700. PubMed ID: 4027900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in breast cancer chemo-endocrine therapy from the survival standpoint].
    Nomura Y
    Gan To Kagaku Ryoho; 1995 May; 22(6):726-31. PubMed ID: 7755380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemo-endocrine therapy of advanced breast cancer].
    Nomura Y
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3214-20. PubMed ID: 2973769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
    Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
    Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy.
    Toi M; Nakamura T; Wada T; Yamamoto A; Toge T; Niimoto M; Hattori T
    Jpn J Surg; 1989 Nov; 19(6):768-72. PubMed ID: 2514309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.